GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Founders of The Entertainer toy chain hand over control to workers - Global Banking & Finance Review
Image depicting the founders of The Entertainer, Gary and Catherine Grant, announcing the transition of their toy retailer to employee ownership, emphasizing the significance of this move in the finance sector.
Finance

Holding firm Exor to raise bioMerieux stake to around 8.5%

Published by Global Banking & Finance Review

Posted on November 19, 2026

1 min read

· Last updated: November 19, 2026

Add as preferred source on Google

Exor Raises bioMerieux Stake to 8.5% Through Institut Mérieux Deal

Exor Increases Investment in bioMérieux

Details of the Stake Increase

Nov 19 (Reuters) - Investment company Exor said on Thursday it was raising its stake in bioMérieux to 8.53% from 3.87%, with the aim of becoming a long-term investor, citing confidence in the French biotechnology firm. 

Transaction Structure

The transaction will be carried out through an exchange of Exor's shares and voting rights in Institut Mérieux for those in bioMérieux. Institut Mérieux will remain bioMérieux's majority shareholder with 55.24% of the share capital and 68.67% of voting rights.

Key Points of the Deal
  • The deal is expected to be completed in December, with Exor set to increase its voting rights in bioMérieux to 5.35%
  • The investment arm of Italy's Agnelli family currently holds a 10% stake and 5.3% of voting rights in Institut Mérieux
  • After completion of the deal, it will hold 5.02% of Institut Merieux's shares and 2.58% of voting rights
  • Exor values bioMerieux greatly for its leadership in diagnostics and wants to support it over the long term, CEO John Elkann said

Reporting and Editorial Information

(Reporting by Margaux Perrin in Gdansk, editing by Milla Nissi-Prussak)

Key Takeaways

  • Exor boosts its direct ownership in bioMérieux to 8.53% and will gain 5.35% voting rights, signaling long-term confidence in the diagnostic leader. (globenewswire.com)
  • Institut Mérieux remains majority owner of bioMérieux with 55.24% of capital and 68.67% of voting rights post-transaction. (globenewswire.com)
  • The stake transfer occurs through a capital reduction at Institut Mérieux; Exor’s holding in Institut Mérieux will drop to 5.02% of capital and 2.58% of voting rights. (globenewswire.com)
  • The transaction, due in December 2026, is subject to creditor objections and shareholder approval at Institut Mérieux. (globenewswire.com)
  • Exor first invested in Institut Mérieux in 2022 and started holding bioMérieux shares directly in 2025; the move reflects continued engagement and support for diagnostics innovation. (exor.com)

References

Frequently Asked Questions

What is Exor's new stake in bioMerieux?
Exor is raising its stake in bioMerieux to 8.53%, up from 3.87%, through a share exchange with Institut Mérieux.
How will the transaction be carried out?
The transaction involves exchanging Exor’s shares and voting rights in Institut Mérieux for those in bioMerieux.
Who will remain the majority shareholder in bioMerieux?
Institut Mérieux will remain bioMerieux's majority shareholder, holding 55.24% of the share capital.
When is the deal expected to be completed?
The deal is expected to be completed in December.
Why is Exor increasing its investment in bioMerieux?
Exor aims to become a long-term investor in bioMerieux, citing confidence in the company's leadership in diagnostics.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category